Supreme Court of the United States / October Term 2011

Caraco Pharmaceutical Laboratories, Ltd., et al., Petitioners v. Novo Nordisk A/s et al.

Decided April 17, 2012. Elena Kagan delivered the opinion of the Court.

Docket 10-844 · 566 U.S. 399 (2012) · Cited 209 times

Holding

A generic manufacturer may employ the counterclaim provision to force correction of a use code that inaccurately describes the brand’s patent as covering a particular method of using a drug.

The Court’s statement of the holding, from the opinion’s syllabus. The syllabus is prepared by the Reporter of Decisions and is not part of the opinion of the Court — read the official opinion for authority.

How the Justices voted

Decided 9–0.

“Concurring” means agreeing with the outcome; any split shown is the Court’s judgment, not each Justice’s reasoning. Source: the Supreme Court Database (Spaeth et al.), Washington University.

Precedents cited

Supreme Court decisions this opinion relies on, ordered by how often it cites each. Cases in our collection link through; others are named.

Cited by

Later Supreme Court opinions in our collection that cite this case.

Official text

Read the official opinion (U.S. Reports, govinfo.gov)

Explore from here

Elena Kagan’s profile · All Supreme Court opinions · The Supreme Court

Source: Supreme Court of the United States, slip opinions (2012). Citation count from the Free Law Project’s CourtListener bulk data. Data last verified 2026-07-03. Informational only; verify against the primary source before relying. Not a consumer report (FCRA).